Beschreibung
Proposed molecular pathway through which BDMC antagonizes Alzheimer's disease involves SIRT1 upregulation, reduced oxidative stress, and inhibition of amyloid-beta-induced apoptosis. The SIRT1/Nrf2 axis is a key mediator.
Figure 6
DiagramSource Paper
Bisdemethoxycurcumin inhibits oxidative stress and antagonizes Alzheimer's disease by up-regulating SIRT1.Cite This Figure
![Figure 6: Proposed molecular pathway through which BDMC antagonizes Alzheimer's disease involves SIRT1 upregulation, reduced oxidative stress, and inhibition of amyloid-beta-induced apoptosis. The SIRT1/Nrf2 axis is a key mediator.]() > Source: Yan Xu et al. "Bisdemethoxycurcumin inhibits oxidative stress and antagonizes Alzheimer's disea." *Brain and behavior*, 2020. PMID: [32441492](https://pubmed.ncbi.nlm.nih.gov/32441492/)
<figure> <img src="" alt="Proposed molecular pathway through which BDMC antagonizes Alzheimer's disease involves SIRT1 upregulation, reduced oxidative stress, and inhibition of amyloid-beta-induced apoptosis. The SIRT1/Nrf2 axis is a key mediator." /> <figcaption>Figure 6. Proposed molecular pathway through which BDMC antagonizes Alzheimer's disease involves SIRT1 upregulation, reduced oxidative stress, and inhibition of amyloid-beta-induced apoptosis. The SIRT1/Nrf2 axis is a key mediator.<br> Source: Yan Xu et al. "Bisdemethoxycurcumin inhibits oxidative stress and antagonizes Alzheimer's disea." <em>Brain and behavior</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32441492/">32441492</a></figcaption> </figure>